ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2015
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials.BMC psychiatry · 2025Pooled it
- Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.BMC psychiatry · 2020Pooled it
- A review of Indian research on co-occurring cannabis use disorders& psychiatric disorders.The Indian journal of medical research · 2017Pooled it
- Exposotypes in psychotic disorders.Scientific reports · 2025Article
- CB1 receptor and psychosis: friend, foe, or both.Frontiers in psychiatry · 2025Article
- The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis-The Case of the Xanomeline-Trospium Combination: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Capsaicin alleviates neuronal apoptosis and schizophrenia-like behavioral abnormalities induced by early life stress.Schizophrenia (Heidelberg, Germany) · 2023Article
- Inhibitors of Endocannabinoids' Enzymatic Degradation as a Potential Target of the Memory Disturbances in an Acute N-Methyl-D-Aspartate (NMDA) Receptor Hypofunction Model of Schizophrenia in Mice.International journal of molecular sciences · 2023Article
- Prevalence and association of non-medical cannabis use with post-procedural healthcare utilisation in patients undergoing surgery or interventional procedures: a retrospective cohort study.EClinicalMedicine · 2023Article
- Cannabis consumption and prosociality.Scientific reports · 2022Article
- Cannabidiol Attenuates MK-801-Induced Cognitive Symptoms of Schizophrenia in the Passive Avoidance Test in Mice.Molecules (Basel, Switzerland) · 2021Article
- The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases.International journal of molecular sciences · 2021Review
- The link among microbiota, epigenetics, and disease development.Environmental science and pollution research international · 2021Review
- Cannabidiol in the Treatment of Epilepsy.Clinical drug investigation · 2021Review
- The antipsychotic potential of cannabidiol: clinical implications for patients with psychosis and comorbid cannabis use disorder.Journal of psychiatry & neuroscience : JPN · 2021Article
- The therapeutic role of Cannabidiol in mental health: a systematic review.Journal of cannabis research · 2020Review
- Differential effects of Δ9-tetrahydrocannabinol dosing on correlates of schizophrenia in the sub-chronic PCP rat model.PloS one · 2020Article
- Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions.Adolescent health, medicine and therapeutics · 2020Article
- Determining Risks for Cannabis Use Disorder in the Face of Changing Legal Policies.Current addiction reports · 2019Article
- Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and Traits.JAMA psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a unique clinical phenotype, and several genetic polymorphisms may modulate the relationship between cannabis use and psychosis. The endocannabinoid system has been implicated in psychosis both related and unrelated to cannabis exposure, and studying this system holds potential to increase understanding of the pathophysiology of schizophrenia. Anandamide signaling in the central nervous system may be particularly important. Δ(9)-Tetrahydrocannabinol in cannabis can cause symptoms of schizophrenia when acutely administered, and cannabidiol (CBD), another compound in cannabis, can counter many of these effects. CBD may have therapeutic potential for the treatment of psychosis following cannabis use, as well as schizophrenia, possibly with better tolerability than current antipsychotic treatments. CBD may also have anti-inflammatory and neuroprotective properties. Establishing the role of CBD and other CBD-based compounds in treating psychotic disorders will require further human research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.